Biochemistry

Calico Appoints Michael Lenardo, M.D., as Chief Scientific Officer

Retrieved on: 
Thursday, March 28, 2024
Internal medicine, University, Natural science, Biomedicine, Alphabet, Calico (company), Immune system, SAN, Research, Science, Whitehead Institute, National academy, Biology, Biochemistry, Johns Hopkins University, NIAID, Most, Nobel, Bangladesh Technical Education Board, Birth, Biomedical Research, O.B.E, Infection, Ageing, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 28, 2024 /PRNewswire/ -- Calico Life Sciences LLC (Calico), a biotechnology organization focused on the biology of aging and age-related diseases, and founded by Alphabet and Arthur D. Levinson, Ph.D., today announced the appointment of Michael Lenardo, M.D., as its new Chief Scientific Officer.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 28, 2024 /PRNewswire/ -- Calico Life Sciences LLC (Calico), a biotechnology organization focused on the biology of aging and age-related diseases, and founded by Alphabet and Arthur D. Levinson, Ph.D., today announced the appointment of Michael Lenardo, M.D., as its new Chief Scientific Officer.
  • Dr. Lenardo is an accomplished molecular immunologist and geneticist whose medical research career spans four decades.
  • "Securing someone of Mike's caliber for the critical role of Chief Scientific Officer is a major achievement for Calico," said Dr. Levinson, CEO of Calico.
  • "The commitment to scientific excellence and integrity at Calico, coupled with the highly talented team, is truly impressive and reflected in the impactful progress they are making.

International Harrington Prize Awarded to Dr. Arlene Sharpe

Retrieved on: 
Tuesday, March 19, 2024
LDL, Human papillomavirus infection, Patient, DSM-IV codes, Lecture, National Cancer Institute, Harvard University, Creativity, AAP, PD-1, Massachusetts General Hospital, Science, Diabetes, Marfan syndrome, All India Mahila Congress, Immunology, AUC, NIH, Cancer, Nivolumab, Immune system, Biochemistry, Harvard Medical School, Cervical cancer, Research, University, Antibody, ASCI, FDA, Mount Sinai Hospital, Sickle cell disease, University of Pennsylvania, PCSK9, COVID-19, Doctor of Philosophy, Biology, Kidney, Thalassemia, Johns Hopkins University, Society, Division, Leptin, Pharmaceutical industry

CLEVELAND, March 19, 2024 /PRNewswire/ -- The eleventh annual Harrington Prize for Innovation in Medicine has been awarded to Arlene H. Sharpe, MD, PhD, Kolokotrones University Professor and Chair of the Department of Immunology at Harvard Medical School. The award recognizes her breakthrough discoveries in immune regulation, which have established foundational principles in immunology and led to new cancer therapies that act by boosting the immune response to cancer.

Key Points: 
  • CLEVELAND, March 19, 2024 /PRNewswire/ -- The eleventh annual Harrington Prize for Innovation in Medicine has been awarded to Arlene H. Sharpe, MD, PhD, Kolokotrones University Professor and Chair of the Department of Immunology at Harvard Medical School.
  • Her work helped identify key pathways that restrain the activity of T lymphocytes (immune cells) to fight cancer.
  • A committee composed of members of the ASCI Council and the Harrington Discovery Institute Scientific Advisory Board reviewed nominations from leading academic medical centers globally before selecting the 2024 Harrington Prize recipient.
  • 2023: Jean Bennett, MD, PhD, and Albert M. Maguire, MD, for their groundbreaking translational research to restore sight in inherited genetic diseases.

Delcath Systems Appoints Martha S. Rook as Chief Operating Officer

Retrieved on: 
Monday, March 18, 2024
DSM-IV codes, Harvard Medical School, Employment, MIT, Delcath Systems, Knowledge, Gene, Gene editing, Molecular biology, Senior, Doctor of Philosophy, Biochemistry, Chemistry, Texas A&M University, Compensated emancipation, Liver, Sigma-Aldrich, Pharmaceutical industry

NEW YORK, March 18, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Martha S. Rook as its new Chief Operating Officer (COO).

Key Points: 
  • NEW YORK, March 18, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Martha S. Rook as its new Chief Operating Officer (COO).
  • Martha S. Rook, Ph.D., is an experienced industry leader who brings more than 25 years of academic and industry experience in molecular biology, diagnostics development, biologics process development and biologics manufacturing.
  • She joins Delcath from insitro where she served as a Chief Technical Operations Officer and was responsible for core research services, facilities and laboratory operations, quality and project and portfolio management.
  • "We are thrilled to welcome Martha, a Senior business leader with more than 25 years of experience, to the leadership team," said Gerard Michel, Chief Executive Officer of Delcath.

Google Canada announces new research grants to bolster Canada's AI ecosystem

Retrieved on: 
Monday, March 18, 2024
Research, Automation, University of Alberta, Google.org, Organization, Climate change, Partnership, Education, Knowledge, Ethics, V&A Digital Futures, Public policy, Policy, Expert, Water purification, Life, Carbon, Biology, Carbon cycle, Biochemistry, Government, Chemistry, Water quality, International Center, Medical device

From its first-rate education system to world-class researchers, there's been a surge in AI knowledge and expertise over the last decade.

Key Points: 
  • From its first-rate education system to world-class researchers, there's been a surge in AI knowledge and expertise over the last decade.
  • "We look forward to supporting these organizations to propel Canada's AI momentum and shape a brighter future that benefits all Canadians."
  • The funding will also support CIFAR's work to promote responsible AI research and development.
  • "Advancing Responsible AI is a core tenet of CIFAR's work through the Pan-Canadian AI Strategy," said Elissa Strome, Executive Director, Pan-Canadian AI Strategy at CIFAR.

Dominari Securities LLC Expands Investment Banking Practice with Appointment of Experienced Financial Executive

Retrieved on: 
Tuesday, March 12, 2024
Biochemistry, MSRB, McGill University, Medical research, Research fellow, Health, Oncogene, FDIC, Karolinska Institute, Research, CRS, Investment Banking Exam, Investment banking, Senior, Virology, Investment, Breast cancer, Mission, FINRA, SIPC, Security (finance)

NEW YORK, March 12, 2024 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH) (the "Company") today announced its wholly-owned subsidiary, Dominari Securities LLC, has appointed Dr. Cosme Ordoñez to the role of Head of Investment Banking, Investment Banking Principal and bolstering the firm's coverage in the healthcare sector.

Key Points: 
  • Mr. Kyle Wool, CEO of Dominari Securities LLC, commented, "We are thrilled to welcome Cosme to the firm to head up our investment banking practice.
  • Securities Brokerage and Registered Investment Adviser Services are offered through Dominari Securities LLC, a Member of FINRA, MSRB and SIPC.
  • You can check the background of Dominari Securities and its registered investment professionals and review its SEC Form CRS on FINRA's BrokerCheck site at https://brokercheck.finra.org .
  • Information for Dominari Securities LLC and its registered investment professionals as well as its SEC Form CRS may also be found on FINRA's BrokerCheck site.

Trinity University Receives Largest Gift in the University’s History for Naming of the D. R. Semmes School of Science

Retrieved on: 
Friday, March 8, 2024
Physics, Trinity University, Computer science, Research, Education, DoorDash, STEM, Mentorship, Molecular biology, Learning, Astronomy, Texas Biomedical Research Institute, Biochemistry, Faculty, University, School, History, Human, Council, Support, Southwest Research Institute, Microsoft, Advancement, Software, Student, Management

San Antonio, March 08, 2024 (GLOBE NEWSWIRE) -- With the largest gift in Trinity University’s history at $26.5 million, the University is honored to announce the naming of the D. R. Semmes School of Science .

Key Points: 
  • San Antonio, March 08, 2024 (GLOBE NEWSWIRE) -- With the largest gift in Trinity University’s history at $26.5 million, the University is honored to announce the naming of the D. R. Semmes School of Science .
  • “This investment by the Semmes Foundation accelerates our goal to deliver the best undergraduate science education in the United States,” said Vanessa B. Beasley, Ph.D., President of Trinity University.
  • “The sciences are at the core of a broad liberal arts education, and Trinity fundamentally understands this.
  • “We look forward to collaborating with Trinity and offering its students real-world experience in the sciences.”
    The history between the Semmes Foundation and Trinity University runs deep.

Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024

Retrieved on: 
Friday, March 8, 2024
Assay, Cancer, JNK, NLRP3, AACR, IIS, Biochemistry, Cellular, Therapy, Reactive oxygen species, Tumor microenvironment, Patient, ROS, Research, Pharmaceutical industry

“The ability to impact multiple targets is an important characteristic of Onconova’s two lead clinical programs, rigosertib and narazaciclib.

Key Points: 
  • “The ability to impact multiple targets is an important characteristic of Onconova’s two lead clinical programs, rigosertib and narazaciclib.
  • We are pleased to present new preclinical studies that explore the molecular targets for rigosertib, in clinical development through a series of investigator initiated studies (IIS),” commented Steven Fruchtman, M.D., President and Chief Executive Officer of Onconova.
  • “The studies provide additional prospective on the main cellular pathways impacted by rigosertib, including RAS-MAPK signaling and reactive oxygen species (ROS)-related proteins.
  • Conclusions: This work identified a series of cellular and inflammatory targets that may be affected by rigosertib.

Sister Mary Glennon Scholarship Recipients Announced at Misericordia University for 2024-2025 Academic Year

Retrieved on: 
Monday, March 4, 2024
Admitted, Psychology, Chemistry, Physical, GPA, Outline of health sciences, Occupational therapy, University, Specialization, Business administration, Pre-medical, Medicine, Misericordia University, RSM, Biochemistry, Student, Nursing

Dallas Twp., PA, March 04, 2024 (GLOBE NEWSWIRE) -- Misericordia University recently selected the seventh annual group of incoming students to receive the merit-based, full-tuition Sister Mary Glennon ’62 Scholarships for the Fall 2024- Spring 2025 academic year.

Key Points: 
  • Dallas Twp., PA, March 04, 2024 (GLOBE NEWSWIRE) -- Misericordia University recently selected the seventh annual group of incoming students to receive the merit-based, full-tuition Sister Mary Glennon ’62 Scholarships for the Fall 2024- Spring 2025 academic year.
  • The six recipients of the  Sister Mary Glennon ’62 Scholarships scheduled to enroll in Fall ’24 are:
    Dylan Ramirez from Easton, PA, who plans to pursue a Business Administration degree with a Management specialization.
  • We are confident that they will excel in our supportive campus community, significantly contribute to their respective fields, and become future industry leaders.”
    The scholarship is named in honor of Misericordia University’s longest-serving academic dean, Sister Mary Glennon, Ph.D., RSM.
  • For more information on Sister Mary Glennon ’62 Scholarships please visit, www.misericordia.edu/financial-aid/scholarship/sr-mary-glennon-scholarships , and for more information about applying to Misericordia University please visit, www.misericordia.edu .

Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors

Retrieved on: 
Monday, March 4, 2024
Gene editing, Takeda Pharmaceutical Company, Neoplasm, Investment, Pfizer, Drug discovery, University, CFA, New Enterprise Associates, Proteomics, Doctor of Philosophy, NEA, Therapy, Patient, Radiopharmaceutical, ACRV, Medicine, AP3, Texas A&M University, Chemical engineering, Columbia University, Cowen Inc., Research, PFM, Biochemistry, Pharmaceutical industry

Dr. Palani added, “Acrivon is an entirely science-based company and its AP3 platform is a ground-breaking approach which is broadly applicable across drug discovery and development with significant unrealized potential -- not only in oncology but also in other areas including autoimmune and metabolic disorders, as dysregulated signaling ultimately underlies all diseases. The company currently is focused on oncology with a highly differentiated profile in this space. I am excited to join a distinguished board and support the full realization of the potential of the platform applied to the company’s current pipeline and beyond.”

Key Points: 
  • “Santhosh previously served as an advisor to Acrivon and has a deep understanding and appreciation of the breadth and novelty of our next generation precision medicine platform,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics.
  • At PFM, Dr. Palani led public and private biotechnology investments, and served on the board of companies in the cell therapy and gene editing fields.
  • Prior to Cowen, Dr. Palani was in oncology drug development at Pfizer Inc. and Takeda Pharmaceuticals.
  • I am excited to join a distinguished board and support the full realization of the potential of the platform applied to the company’s current pipeline and beyond.”

Fish & Richardson Expands Life Sciences Industry Team with Addition of Louis Fogel and Shaun Van Horn

Retrieved on: 
Wednesday, February 28, 2024
Legal, Professional Services, Multimedia, Chemistry, Fish & Richardson, Jenner & Block, Molecular biology, University, Savoy Hotel, University School, Risk, Intellectual property, Patent, Associate, IP, Senior counsel, Immortalised cell line, DNA, Biochemistry

Intellectual property law firm Fish & Richardson is pleased to welcome seasoned litigators Louis Fogel, Ph.D., and Shaun Van Horn.

Key Points: 
  • Intellectual property law firm Fish & Richardson is pleased to welcome seasoned litigators Louis Fogel, Ph.D., and Shaun Van Horn.
  • The pair, who are based in Chicago, join Fish’s Litigation Group and are members of the Life Sciences Industry Team.
  • View the full release here: https://www.businesswire.com/news/home/20240228410387/en/
    Fish & Richardson Principal Louis Fogel (Photo: Business Wire)
    “Louis and Shaun have an impressive record and deep market knowledge in life sciences litigation,” said Global Head of Litigation Corrin Drakulich.
  • “Fish has been a dominant force in life sciences litigation for decades, and I’m thrilled to join this distinguished group,” said Fogel.